Transfusion Medicine and Hemotherapy最新文献

{"title":"The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis.","authors":"Guoxiang Qin,&nbsp;Xueling Han","doi":"10.1159/000526174","DOIUrl":"https://doi.org/10.1159/000526174","url":null,"abstract":"<p><strong>Objective: </strong>Mutations of the tumor protein p53 (TP53) gene were considered to be associated with an unfavorable prognosis in acute myeloid leukemia (AML). This meta-analysis aimed to systematically elucidate the prognostic value of TP53 mutation in adult patients with AML.</p><p><strong>Method: </strong>A comprehensive literature search was conducted for eligible studies published before August 2021. The primary endpoint was overall survival (OS). Pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated for prognostic parameters. Subgroup analyses based on intensive treatment were performed.</p><p><strong>Results: </strong>Thirty-two studies with 7,062 patients were included. As compared to wild-type carriers, AML patients with TP53 mutations had significantly shorter OS (HR: 2.40, 95% CI: 2.16-2.67, <i>I</i>²: 46.6%). Similar results were found in DFS (HR: 2.87, 95% CI: 1.88-4.38), EFS (HR: 2.56, 95% CI: 1.97-3.31), and RFS (HR: 2.40, 95% CI: 1.79-3.22). Mutant TP53 predicted inferior OS (HR: 2.77, 95% CI: 2.41-3.18) in the intensively treated AML subgroup, compared with the non-intensively treated group (HR: 1.89, 95% CI: 1.58-2.26). Among intensively-treated AML patients, the age of 65 did not affect the prognostic value of TP53 mutations. Besides, TP53 mutation was also strongly associated with an elevated risk of adverse cytogenetics, which conferred a dismal OS in AML patients (HR: 2.03, 95% CI: 1.74-2.37).</p><p><strong>Conclusion: </strong>TP53 mutation exhibits a promising potential for discriminating AML patients with a worse prognosis, thus being capable of serving as a novel tool for prognostication and therapeutic decision-making in the management of AML.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/32/tmh-0050-0234.PMC10331159.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10172605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red Blood Cell Omics and Machine Learning in Transfusion Medicine: Singularity Is Near.","authors":"Angelo D'Alessandro","doi":"10.1159/000529744","DOIUrl":"https://doi.org/10.1159/000529744","url":null,"abstract":"<p><strong>Background: </strong>Blood transfusion is a life-saving intervention for millions of recipients worldwide. Over the last 15 years, the advent of high-throughput, affordable omics technologies - including genomics, proteomics, lipidomics, and metabolomics - has allowed transfusion medicine to revisit the biology of blood donors, stored blood products, and transfusion recipients.</p><p><strong>Summary: </strong>Omics approaches have shed light on the genetic and non-genetic factors (environmental or other exposures) impacting the quality of stored blood products and efficacy of transfusion events, based on the current Food and Drug Administration guidelines (e.g., hemolysis and post-transfusion recovery for stored red blood cells). As a treasure trove of data accumulates, the implementation of machine learning approaches promises to revolutionize the field of transfusion medicine, not only by advancing basic science. Indeed, computational strategies have already been used to perform high-content screenings of red blood cell morphology in microfluidic devices, generate in silico models of erythrocyte membrane to predict deformability and bending rigidity, or design systems biology maps of the red blood cell metabolome to drive the development of novel storage additives.</p><p><strong>Key message: </strong>In the near future, high-throughput testing of donor genomes via precision transfusion medicine arrays and metabolomics of all donated products will be able to inform the development and implementation of machine learning strategies that match, from vein to vein, donors, optimal processing strategies (additives, shelf life), and recipients, realizing the promise of personalized transfusion medicine.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/6a/tmh-0050-0174.PMC10331163.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10008156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Big Data in Transfusion Medicine and Artificial Intelligence Analysis for Red Blood Cell Quality Control.","authors":"Marcelle G M Lopes, Steffen M Recktenwald, Greta Simionato, Hermann Eichler, Christian Wagner, Stephan Quint, Lars Kaestner","doi":"10.1159/000530458","DOIUrl":"10.1159/000530458","url":null,"abstract":"<p><strong>Background: </strong>\"Artificial intelligence\" and \"big data\" increasingly take the step from just being interesting concepts to being relevant or even part of our lives. This general statement holds also true for transfusion medicine. Besides all advancements in transfusion medicine, there is not yet an established red blood cell quality measure, which is generally applied.</p><p><strong>Summary: </strong>We highlight the usefulness of big data in transfusion medicine. Furthermore, we emphasize in the example of quality control of red blood cell units the application of artificial intelligence.</p><p><strong>Key messages: </strong>A variety of concepts making use of big data and artificial intelligence are readily available but still await to be implemented into any clinical routine. For the quality control of red blood cell units, clinical validation is still required.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9803407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omics and Machine Learning in Transfusion Medicine.","authors":"Angelo D'Alessandro, Peter Bugert","doi":"10.1159/000530978","DOIUrl":"10.1159/000530978","url":null,"abstract":"","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9803403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Different Expression Profiles of Exosomal circRNAs from Apheresis Platelets during Storage.","authors":"Jingfu Liu, Shan Chen, Zhen Li, Rong Lu, Xianren Ye","doi":"10.1159/000530040","DOIUrl":"https://doi.org/10.1159/000530040","url":null,"abstract":"<p><strong>Introduction: </strong>Bioactive substances of stored platelets change during the stored periods. Exosomes are reported to be increased during platelet storage. Circular RNAs (circRNAs) are one of the main components in exosomes. It is the purpose of this study to investigate the different expression of exosomal circRNAs during storage.</p><p><strong>Methods: </strong>Apheresis platelets were collected from 7 healthy volunteers and stored in platelet storage bags for 1 day or 5 days. We isolated exosomes by ultracentrifugation and characterized exosomes by transmission electron microscopy, nano-flow cytometry, and Western blot. We conducted microarray analysis to detect changes in the exosomal circRNAs from apheresis platelets during storage, and qRT-PCR to validate their expressions. To analyze the competing endogenous RNA (ceRNA) of circRNAs, microRNAs (miRNAs) targets were predicted based on interactions of circRNAs/miRNAs and miRNAs/mRNAs, using TargetScan and miRanda. A ceRNA network was constructed by Cytoscape. The targeted mRNAs were performed for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genome (KEGG) pathway analysis by the DAVID.</p><p><strong>Results: </strong>Microarray analysis revealed that 61 differentially expressed circRNAs between day 1 and day 5. Thirty-one circRNAs of these are upregulated, while 30 circRNAs are downregulated. A ceRNA visualized network includes 9 circRNAs, 48 miRNAs, and 117 mRNAs. There were 117 mRNAs enriched in 203 GO terms and 9 KEGG pathways based on the GO and KEGG pathway enrichment analyses.</p><p><strong>Conclusion: </strong>We identified 61 dysregulated exosomal circRNAs from apheresis platelets during storage. The study provided insights into the underlying mechanisms of platelet storage lesion.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138807461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Identification of Seven Common <i>ABO</i> Alleles by Two-Dimensional Polymerase Chain Reaction Technology.","authors":"Jin Chen, Yuxia Zhan, Jun Zhang, Yang Yu, Shuang Yao, Guanghua Luo","doi":"10.1159/000530013","DOIUrl":"10.1159/000530013","url":null,"abstract":"<p><strong>Introduction: </strong>The molecular biology detection technology of the human <i>ABO</i> blood group system makes up for the limitations in many aspects compared with conventional serological typing technology. This study aimed to establish a new method to identify seven common <i>ABO</i> alleles (<i>ABO</i>*<i>A1.01</i>, <i>ABO</i>*<i>A1.02</i>, <i>ABO</i>*<i>A2.01</i>, <i>ABO</i>*<i>B.01</i>, <i>ABO</i>*<i>O.01.01</i>, <i>ABO</i>*<i>O.01.02</i>, and <i>ABO</i>*<i>O.02.01</i>) by two-dimensional polymerase chain reaction (2D PCR). 2D PCR can identify multiple target genes in a closed test tube by labeling specific primers with tags homologous to the sequence of fluorescently labeled probes, and melting curve analysis is performed after the fluorescent probes are hybridized with tag complementary sequences in PCR-specific products. In this study, 2D PCR and PCR sequence-specific primer (PCR-SSP) were combined to discriminate different alleles in a single reaction, which has the characteristics of high throughput, and compared with other typing techniques; the typing results can be obtained without additional operations.</p><p><strong>Methods: </strong>The <i>ABO</i>*<i>A1.01</i> allele genetic sequence was used as the reference sequence. The specific sense and antisense primers for seven common <i>ABO</i> alleles were designed on exons 6 and 7 according to the principle of 2D PCR and PCR-SSP. Single nucleotide polymorphism sites for identifying seven alleles were detected in FAM and HEX channels, respectively. Two hundred sixty DNA samples were enrolled for rapid <i>ABO</i> genotyping by 2D PCR, and 95 of them were selected for Sanger sequencing. The <i>Kappa</i> test was used to analyze the agreement of the methodologies.</p><p><strong>Results: </strong>These 7 alleles each had four characteristic melting valleys at different single nucleotide polymorphism loci. A total of 15 genotypes were detected, including <i>ABO</i>*<i>A1.01/A1.02</i>, <i>ABO</i>*<i>A1.01/O.01.01</i>, <i>ABO</i>*<i>A1.01/O.01.02</i>, <i>ABO</i>*<i>A1.02/A1.02</i>, <i>ABO</i>*<i>A1.02/O.01.01</i>, <i>ABO</i>*<i>A1.02/O.01.02</i>, <i>ABO</i>*<i>B.01/B.01</i>, <i>ABO</i>*<i>B.01/O.01.01</i>, <i>ABO</i>*<i>B.01/O.01.02</i>, <i>ABO</i>*<i>O.01.01/O.01.01</i>, <i>ABO</i>*<i>O.01.01/O.01.02</i>, <i>ABO</i>*<i>O.01.02/O.01.02</i>, <i>ABO</i>*<i>A1.01/B.01</i>, <i>ABO</i>*<i>A1.02/B.01</i>, and <i>ABO</i>*<i>B.01/O.01. v</i> (containing a rare <i>ABO*O</i> allele, based on the sequencing results). The <i>Kappa</i> test showed completely consistent results for 2D PCR and Sanger sequencing (<i>Kappa</i> = 1).</p><p><strong>Conclusion: </strong>The 2D PCR technique could be used for molecular typing of the ABO blood group, which was efficient, rapid, accurate, and economical.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43799013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Plasma Unit Weight and Donor Sex on Post-Donation Citrate Level: An Experimental Study on Plasmapheresis Donors.","authors":"Chiara Marraccini, Davide Schiroli, Pamela Mancuso, Giuseppe Molinari, Agnese Razzoli, Gaia Gavioli, Tommaso Fasano, Roberto Baricchi, Paolo Giorgi Rossi, Lucia Merolle","doi":"10.1159/000529394","DOIUrl":"10.1159/000529394","url":null,"abstract":"<p><strong>Introduction: </strong>Plasmapheresis donation is considered safe and well tolerated, although long-term effects need to be clarified. The volumes of anticoagulant (ACD-A) used are variable and depend primarily on hematocrit (HCT), total blood processed, amount of plasma collected, and donor characteristics. To elucidate the effect of the plasma unit weight setting on plasmapheresis efficiency and ACD-A distribution, we enrolled male donors undergoing a controlled apheresis process donating 700 g and 720 g in two different sessions. In parallel, we investigated a possible effect of sex, recruiting women donating 700 g of plasma.</p><p><strong>Methods: </strong>The study was conducted on men donating 720 g and (12 months later) 700 g of plasma, and on women donating 700 g of plasma. The main outcomes were pre-/post-donation delta (Δ) citrate concentration in donor plasma and ACD-A reinfused to the donor. Information concerning the annual check-up and the procedure was also collected. Intergroup comparisons (men donating 720 g vs. men donating 700 g and men vs. women both donating 700 g) and intragroup associations with donor and procedural characteristics were reported.</p><p><strong>Results: </strong>With the procedure set at 720 g, the machine processed around 44 mL more whole blood to collect 20 g more plasma, and 720 g donors received around 12 mL more anticoagulant than 700 g donors. Accordingly, Δ citrate concentration was 1.5 times higher (12 μm), with a greater variability observed for 720 g donations. Citrate concentration in the plasma unit was lower in the 720 g group, although not significantly. Comparing outcomes between women and men donating 700 g, we observed higher (and highly variable) Δ citrate and reinfused ACD-A in women, accompanied by lower anticoagulant levels in the unit. Increased Δ citrate is inversely associated with HCT and age in men and with HCT and triglycerides in women. Reinfused ACD-A correlates with HCT in women but not in men.</p><p><strong>Conclusion: </strong>Unit weight setting and sex influence an ACD-A shift from the estimated values toward an increased reinfusion to donor. In parallel, we observed an impact of age and sex on post-donation citrate metabolism. Altogether, these elements should be taken into account for the development of tailored approaches aimed at maintaining similar safety profiles for all donors using different plasmapheresis settings.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44465494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients.","authors":"Liron Miller,&nbsp;Mor Freed-Freundlich,&nbsp;Avichai Shimoni,&nbsp;Tamer Hellou,&nbsp;Abraham Avigdor,&nbsp;Mudi Misgav,&nbsp;Jonathan Canaani","doi":"10.1159/000529595","DOIUrl":"https://doi.org/10.1159/000529595","url":null,"abstract":"<p><strong>Introduction: </strong>Blood product transfusion retains a critical role in the supportive care of patients with acute myeloid leukemia (AML). Whereas previous studies have shown increased transfusion dependency to portend inferior outcome, predictive factors of an increased transfusion burden and the prognostic impact of transfusion support have not been assessed recently.</p><p><strong>Methods/patients: </strong>We performed a retrospective analysis on a recent cohort of patients given intensive induction chemotherapy in 2014-2022.</p><p><strong>Results: </strong>The analysis comprised 180 patients with a median age of 57 years with 80% designated as de novo AML. Fifty-four patients (31%) were <i>FLT3-ITD</i> mutated, and 73 patients (42%) harbored <i>NPM1</i>. Favorable risk and intermediate risk ELN 2017 patients accounted for 43% and 34% of patients, respectively. The median number of red blood cell (RBC) and platelet units given during induction were 9 and 7 units, respectively. Seventeen patients (9%) received cryoprecipitate, and fresh frozen plasma (FFP) was given to 12 patients (7%). Lower initial hemoglobin and platelet levels were predictive of increased use of RBC (<i>p</i> < 0.0001) and platelet transfusions (<i>p</i> < 0.0001). FFP was significantly associated with induction related mortality (42% vs. 5%; <i>p</i> < 0.0001) and with <i>FLT3-ITD</i> (72% vs. 28%; <i>p</i> = 0.004). Blood group AB experienced improved mean overall survival compared to blood group O patients (4.1 years vs. 2.8 years; <i>p</i> = 0.025). In multivariate analysis, increased number of FFP (hazard ratio [HR], 4.23; 95% confidence interval [CI], 2.1-8.6; <i>p</i> < 0.001) and RBC units (HR, 1.8; 95% CI, 1.2-2.8; <i>p</i> = 0.008) given was associated with inferior survival.</p><p><strong>Conclusion: </strong>Transfusion needs during induction crucially impact the clinical trajectory of AML patients.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71414017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Too Early to Abandon Convalescent Plasma for Supportive Treatment of COVID-19.","authors":"Rainer Seitz, Lutz Gürtler, Ute Vahlensieck, Anneliese Hilger, Wolfgang Schramm","doi":"10.1159/000530097","DOIUrl":"10.1159/000530097","url":null,"abstract":"","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45892186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges for Plasma-Derived Medicinal Products.","authors":"Paul F W Strengers","doi":"10.1159/000528959","DOIUrl":"https://doi.org/10.1159/000528959","url":null,"abstract":"<p><strong>Background: </strong>Plasma-derived medicinal products (PDMPs) are medicinal products derived from human plasma, and a number of PDMPs are listed on the WHO Model List of Essential Medicines. These and other PDMPs are crucial for the prophylaxis and treatment of patients with immune deficiencies, autoimmune and inflammatory diseases, bleeding disorders, and a variety of congenital deficiency disorders. The majority of plasma supplies for manufacturing of PDMPs is coming from the USA.</p><p><strong>Summary: </strong>The future of treatments with PDMPs for PDMP-dependent patients depends on the supply of plasma. An imbalance in the global collection of plasma has resulted in regional and global shortages of essential PDMPs. The challenges at different level are mainly related on a balanced and sufficient supply in order to help the patients in need and should be addressed in order to safeguard the treatment with these essential lifesaving and disease mitigating medicines.</p><p><strong>Key messages: </strong>It is advocated to consider plasma as a strategic resource comparable to energy and other rare resources and to investigate whether for the treatment of patients with rare diseases, a free market of PDMPs has its limitations and special protection measures should be developed. At the same time, plasma collections should be increased outside the USA, including in low- and middle-income countries.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/66/tmh-0050-0116.PMC10091012.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9687501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}